cover
Article Per Year (5 Year)
All
Home Page
OAI Link
Editorial Team
Contact
Reviewer
Google Scholar
Contact Name
-
Contact Email
subdirektoratpublikasi.unwar@gmail.com
Phone
+628113960099
Journal Mail Official
editorial.ijbstm@gmail.com
Editorial Address
Universitas Warmadewa, Jl. Terompong 24 Tanjung Bungkak Denpasar Bali, Indonesia
Location
Kota denpasar,
Bali
INDONESIA
International Journal of Biomedical Science and Travel Medicine
Published by Universitas Warmadewa
ISSN : 30477441     EISSN : 30477433     DOI : https://doi.org/10.22225/ijbstm
Core Subject : Health,
Medicine & Pharmacology Public Health
International Journal of Biomedical Science and Travel Medicine is published twice (March and September) a year. The objective is to promote articles on biology and medicine. International Journal of Biomedical Science and Travel Medicine publishes original research work related to biological and medicine. The journal publishes Original articles, Short Reports, Case Reports, and Review articles. All articles published in International Journal of Biomedical Science and Travel Medicine (IJBSTM) are peer-reviewed and published online for immediate access and citation. International Journal of Biomedical Science and Travel Medicine (IJBSTM) publishes the Original clinical and experimental research studies, Review articles, Case reports on topics but not limited to: Biocemistry, Genetics and molecular biology, Medicine, Environmental health, Tropical diseases, Diseases in tropics, Global health, Pharmacological sciences, Biomedical sciences, Public health, Infection, Epidemiology and clinical epidemiology, Molecular biology, Microbiology, Travel Medicine
Arjuna Subject : Kedokteran - Kedokteran (Lain-Lain)
Articles 1 Documents
 1 
Search results for , issue "19-23" : 1 Documents clear
Different Outcome in COVID-19 Patients with or without PPI Use: A Systematic Review and Meta-analysis I Made Wisnu Wardhana; Saraswati Laksmi Dewi
International Journal of Biomedical Science and Travel Medicine 19-23
Publisher : Publication Department, Universitas Warmadewa

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.22225/ijbstm.1.1.2024.19-23

Abstract

Background The coronavirus disease (COVID-19) pandemic still happening and when it’s going to be resolved is not known. In this COVID-19 era, physicians need to better understand the risk and purpose of giving drugs that patients do not need. Proton pump inhibitors (PPI) are sometimes easily prescribed and misused by physicians. The study objective is to find out whether PPI use is associated with better or worse outcomes in patients with COVID-19. Method We searched retrospective studies in various publication libraries like PubMed, Embase, and CENTRAL from 2020 to 2022. Inclusion criteria were studied which differentiated patients with COVID-19 who regularly used PPI and control which is COVID-19 patients who did not use PPI. That study also needs to report the outcomes. The outcome was then divided into two categories which are good outcomes and worse outcomes consisting of severe COVID-19 needing oxygen therapy, admission to intensive care unit (ICU), acute respiratory distress syndrome (ARDS), shock or mortality, to get each study and total odd ratio (OR), 95% confidence interval, and weight. Studies that did not report the outcomes were excluded. We also analyze the data using a fixed or random effect model accordingly and asses the possibility of publication bias using Egger’s test. Case Seven of 11 studies with more than 30.000 COVID-19 patients were analyzed in this study. These patients were divided into 2 groups: patients with COVID-19 who were using PPI up to 30 days before being infected and COVID-19 patients who didn’t use PPI before. The total number of patients in the first group is 3531 patients and the second group is 38138 patients. After statistical analysis, we found that the data is heterogenous with p <0,05, I2 94,22% (95%CI 90,44-96,51%) suggesting the OR needs to be determined in the random effect model. We found that pooled OR is 1.99 (p 0.01, 95% CI, 1.18-3.38). Egger’s test for the possibility of publication bias is 0,64 (95%CI -7,24-4,93). Conclusion COVID-19 patients who use PPI are twice as likely to have a worse outcome than COVID-19 patients who don’t use PPI. This study is statistically significant with a low possibility of publication bias.

Page 1 of 1 | Total Record : 1

 1 

Filter by Year

0000


Reset
Filter By Issues
All Issue 60-64 56-60 52-59 50-55 46-51 45-49 41-45 37-44 35-40 30-36 27-34 24-29 24-28 19-26 19-23 17-23 14-18 12-18 7-16 7-13 7-11 1-6 More Issue